INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
Pulmonary & Nasal Drug Delivery
167
Issue No #167 Nov 2024
November 12th, 2024
Download PDF
Inside the magazine
PULMONARY
Dr Clair Brooks
Copley Scientific
CASCADE IMPACTOR METRICS: EXPLORING NEW GUIDANCE ON DATA ANALYSIS
Clair Brooks, examines the parameters used to quantify and compare the aerodynamic particle size distribution metrics of orally inhaled drug products and methods for calculation, including those laid out in the new USP <1604>, with reference to both “standard” and efficient data analysis metrics to elucidate current debate and establish sufficient understanding for the effective day-to-day application of these methods.
SUSTAINABILITY
Ross Errington
Bespak
REFORMULATING pMDIS WITH NEXT-GENERATION SUSTAINABLE PROPELLANTS
Ross Errington and Simon Gardner, discuss sustainability and the reformulation of pMDIs with low-GWP propellants.
PULMONARY
Andrea Cusack
Nebu~Flow
INNOVATIVE ACOUSTIC NEBULISER TECHNOLOGY
Andrea Cusack, Elijah Nazarzadeh and John Pritchard share insights into the company’s innovative nebuliser platform, designed to overcome the technical restrictions of current technologies that limit the delivery of advanced medicines to the lungs. They also share an update on the development of new digital features for the Nebu-Flow product range.
INTERVIEW
Julien Storz
Aptar Pharma
INTERVIEW: PUREHALE
®
AND THE FUTURE OF FINE MIST DISPENSERS FOR UPPER AIRWAY TREATMENTS
Julien Storz and Giulia Mueller discuss the latest trends and treatment options available for upper airway conditions, along with the many benefits offered by Aptar Pharma’s advanced PureHale
®
systems to manufacturers.
EXPERT VIEW
Mark Parry
TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS
Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.
RESPIRATORY
Dr Marie-Christine Klein
URSATEC
BREEASE – DESIGNED TO ALLEVIATE BREATHING FOR INFANTS AND TODDLERS
Marie-Christine Klein, Christian Weyler and Dr Fredrik Bokvist, discuss the effects of air pollution on health – and how the Breease pacifier could help babies and young children.
EXPERT VIEW
David Webster
ENVIRONMENTAL BENEFITS OF BEDSIDE IONIC NITRIC OXIDE GENERATION
David Webster and Mark Rimkus consider the environmental impact of traditional high-pressure storage systems for nitric oxide and highlight the benefits associated with bedside ionic generation.
PULMONARY
Edgar Hernan Cuevas Brun
HCmed Innovations
IMPROVING AEROSOL DELIVERY: NANOSUSPENSION & MESH TECHNOLOGY
Edgar Hernan Cuevas Brun and Yuchi Chen, discuss how the combination of Formosa’s APNT formulation technology and HCmed’s AdheResp smart breath-actuated mesh nebuliser can work together to offer significant benefits to the aerosolisation of difficult solution-based formulations for inhalation.
NASAL
Mark Ignaczak
Catalent Pharma Solutions
STRATEGIES FOR SELECTING THE RIGHT CDMO FOR NASAL DRUG DELIVERY
Mark Ignaczak explores the current nasal drug delivery landscape and outlines key considerations for choosing the right CDMO to ensure the success of nasal drug projects.
SUSTAINABILITY
Nick Smalley
Kindeva
THE pMDI DILEMMA: MANAGING PATIENT NEEDS, HEALTH AND THE PLANET
Nick Smalley discusses the balancing act involved in meeting patients’ therapeutic needs while protecting the planet when it comes to pMDI development.
INTERVIEW
Alastair Willoughby
Team Consulting
Pharmapack Preview: An INTERVIEW with ALASTAIR WILLOUGHBY
CPHI Milan this year included a key discussion led by Team Consulting’s Alastair Willoughby on “Understanding the Problem of Decarbonisation in Drug Delivery”; one of the industry’s critical challenges. These themes will be discussed in greater depth at Pharmapack Europe in Paris in January.
Top
